Relay Therapeutics Inc. (RLAY)
2.73
-0.26 (-8.70%)
At close: Mar 28, 2025, 3:58 PM
2.71
-0.54%
After-hours: Mar 28, 2025, 06:59 PM EDT
-8.70% (1D)
| Bid | 2.71 |
| Market Cap | 461.95M |
| Revenue (ttm) | 10.14M |
| Net Income (ttm) | -342.12M |
| EPS (ttm) | -2.36 |
| PE Ratio (ttm) | -1.15 |
| Forward PE | -1.81 |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 2,673,054 |
| Avg. Volume (20D) | 2,615,894.9 |
| Open | 2.95 |
| Previous Close | 2.99 |
| Day's Range | 2.69 - 2.98 |
| 52-Week Range | 2.69 - 10.72 |
| Beta | 1.65 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for pa...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2020
Employees 261
Stock Exchange NASDAQ
Ticker Symbol RLAY
Website https://www.relaytx.com
Analyst Forecast
According to 10 analyst ratings, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 560.55% from the latest price.
Stock ForecastsNext Earnings Release
Relay Therapeutics Inc. is scheduled to release its earnings on May 1, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+12.42%
Relay Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+6.71%
Relay Therapeutics shares are trading are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $18 to $19.
